Attached files
file | filename |
---|---|
EX-99.3 - PRESS RELEASE, DATED NOVEMBER 13, 2018 - ENDRA Life Sciences Inc. | ndra_ex99-3.htm |
EX-99.2 - PRESS RELEASE, DATED NOVEMBER 8, 2018 - ENDRA Life Sciences Inc. | ndra_ex99-2.htm |
EX-5.1 - OPINION OF K&L GATES LLP - ENDRA Life Sciences Inc. | ndra_ex5-1.htm |
EX-1.1 - UNDERWRITING AGREEMENT, DATED NOVEMBER 8, 2018 - ENDRA Life Sciences Inc. | ndra_ex1-1.htm |
8-K - ENDRA LIFE SCIENCES INC. - ENDRA Life Sciences Inc. | ndra_form8-k.htm |
Exhibit 99.1
ENDRA
Life Sciences Announces Proposed Public Offering of Common
Stock
ANN ARBOR, Michigan – November 7, 2018 – ENDRA
Life Sciences Inc. (“ENDRA” or the
“Company”) (NASDAQ: NDRA), a developer of enhanced
ultrasound technologies, is proposing to offer and sell, subject to
market conditions, shares of its common stock in an underwritten
public offering. ENDRA expects to grant the underwriter a 45-day
option to purchase up to an additional 15 percent of the shares of
common stock offered in the public offering to cover
over-allotments, if any. All of the common shares are being offered
by the Company. The final terms of the offering will depend on
market and other conditions at the time of pricing, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the
offering.
National
Securities Corporation, a wholly owned subsidiary of National
Holdings Corporation (NASDAQ: NHLD), is acting as sole book-running
manager for the proposed offering.
A shelf
registration statement on Form S-3 relating to the shares of common
stock being offered was filed with the Securities and Exchange
Commission (the “SEC”) and is effective. Copies of the
final prospectus supplement and the accompanying base prospectus
relating to this offering may be obtained, when available,
from: National Securities Corporation,
Attention: Christopher Passarelli, 200 Vesey Street, 25th Floor,
New York, New York 10281, telephone: (212) 417-8164 or by email
at prospectusrequest@nationalsecurities.com; or on the SEC’s website at
http://www.sec.gov.
This announcement shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful.
About ENDRA Life Sciences Inc.
ENDRA
Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of
enhanced ultrasound technologies. ENDRA is developing a next
generation Thermo-Acoustic Enhanced UltraSound (TAEUS™)
platform to enable clinicians to visualize human tissue
composition, function and temperature in ways previously possible
only with CT & MRI - at a fraction of the cost, and at the
point-of-care. ENDRA's first TAEUS application will focus on the
quantification of fat in the liver, for early detection and
monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's
goal is to bring new capabilities to ultrasound - thereby
broadening access to better healthcare. For more information,
please visit www.endrainc.com.
About Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD
is a condition closely associated with obesity, diabetes,
hepatitis-C and certain genetic predispositions in which fat
accumulates in the liver. NAFLD affects over 1 billion people
globally and is estimated to cost the U.S healthcare system over
$100B annually. NAFLD is often asymptomatic and if left untreated,
NAFLD can progress to inflammation (NASH), tissue scarring
(fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD
is forecast to be the greatest root cause of liver transplants. The
only tools currently available for diagnosing and monitoring NAFLD
are impractical: expensive Magnetic Resonance Imaging (MRI) or an
invasive surgical biopsy.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management
has based any forward-looking statements included in this release
on its current expectations, the information on which such
expectations were based may change. Forward-looking statements
involve inherent risks and uncertainties which could cause actual
results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks
and uncertainties described in the Risk Factors and in
Management’s Discussion and Analysis of Financial Condition
and Results of Operations sections of our recently filed
Registration Statement on Form 10-K, which can be found on the
SEC’s website at www.sec.gov. We urge you to consider those
risks and uncertainties in evaluating our forward-looking
statements. We caution readers not to place undue reliance upon any
such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws,
we disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Company Contact
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Media & Investor Relations Contact
Chris Tyson
Managing Director
MZ North America
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us